# Caribou (CRBU) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CRBU
## Company Profile
- Ticker: CRBU
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Gene Therapy, Oncology
## Stock Data
- Close: 1.7 USD
- Market cap: 230098933.99999997 USD
- Last updated: 2026-08-12
## Business Overview
### Allogeneic Cell Therapy
Caribou Biosciences develops off-the-shelf CAR-T cell therapies using its CRISPR genome-editing platform. Its candidates incorporate multiple edits intended to improve persistence, antitumor activity and compatibility with donor-derived cells.
### Vispa-cel
Vispacabtagene regedleucel, or vispa-cel, is an allogeneic anti-CD19 CAR-T therapy with a PD-1 knockout. Development is focused on relapsed or refractory B-cell non-Hodgkin lymphoma, including a pivotal path in second-line large B-cell lymphoma.
### ANTLER-3 Pivotal Strategy
The planned ANTLER-3 study is designed to establish vispa-cel as an immediately available alternative to autologous CAR-T therapy in second-line large B-cell lymphoma.
### CB-011
CB-011 is an allogeneic anti-BCMA CAR-T candidate being evaluated in the Phase 1 CaMMouflage study for relapsed or refractory multiple myeloma.
## Why The Stock Is Moving

The latest monitored company update is “Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Initial dose-expansion data for CB-011 in BCMA-naive and BCMA-exposed multiple myeloma in the second half of 2026.

## Recent News
- 2026-08-13 20:05 EST — [Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CRBU/caribou-biosciences-reports-second-quarter-2026-financial-results-and-provides-b-be779dff) — Source: Caribou
- 2026-06-29 12:00 EST — [Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-h-c-wainwright-4th-annual-cell-therapy-faa61d70) — Source: Caribou
- 2026-06-11 12:01 EST — [Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026](https://biopharmsignal.com/news/CRBU/caribou-biosciences-reports-long-term-vispa-cel-data-in-second-line-large-b-cell-167f9970) — Source: Caribou
- 2026-06-11 12:00 EST — [Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting](https://biopharmsignal.com/news/CRBU/caribou-biosciences-reports-dose-escalation-durability-data-for-cb-011-at-the-20-12c09675) — Source: Caribou
- 2026-05-27 20:05 EST — [Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/CRBU/caribou-biosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference) — Source: Caribou